TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07547228: Phase I/II Study to Assess Safety and Efficacy of PRL3-zumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Sponsor: Intra-IMMUSG Pte Ltd · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$2,596,240

Rescue Site Savings

+$1,721,420

Unlock Full NCT07547228 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07547228 Rescue Dossier →